anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Depression and anxiety during both pregnancy and postnatal periods are major public health problems, with those living in developing countries being most vulnerable. Alterations in biological rhythms, sleep disturbances, and low daylight exposure have been linked with higher risk for these problems. When considering conditions that are known to produce misalignment, the perinatal period could be seen as a standalone model in which there are distinct challenges to the temporal program. Prior evidence suggests that both sleep onset latency and sleep deficits increases risk for symptoms of postnatal depression. In fact, sleep disturbances appear among the most common risk factors for postnatal depression and are linked to a four-fold increased risk for depression. Emerging evidence indicates that changes in factors related to circadian health, such as patterns of sleep, activity, and light exposure, affect mood during the peripartum period. Thus, chronobiological interventions may be promising strategies, from prevention to treatment. Thus, the Randomised Clinical Trial (RCT) aims to evaluate the effectiveness of Blue Light Therapy (BlueLT) in women with postpartum depression, and examine the alignment of rest-activity and internal body time as mediating variables. During the RCT, we will assess chronobiological factors and their implications on the health/disease process. The chronobiological factors that will be studied are rest-activity rhythms, levels of light exposure, temperature rhythms, sleep duration and phase, social jetlag, and BodyTime (a simple assay from a single blood sample taken at any time of the day). We will recruit women until we ensure the sample size for our nested BlueLT RCT: 50 women with postpartum depression, with 25 in the intervention group (BlueLT) and 25 in the placebo group (ControlLT), along with 100 healthy controls. The BlueLT device is equipped with a narrow band short wavelength Light Emitting Diode (LED) - wavelength peak(λp) of \~470 nm (blue). The ControlLT (placebo) device is equipped with a dim long-wavelength enriched LED. Because pregnancy and postpartum are periods at which changes in phase relationships may happen as an adaptation and not necessarily be disease-promoting will also selected Healthy Control group from the cohort. This group will be the control for changes unrelated to the diagnosis of depression or placebo/treatment effects that may be present. The exclusion criterias are: history of major depressive or anxiety disorder, current psychotic disorder, night shift worker, active suicidal ideation or psychotic symptoms, unstable general medical conditions that interfere with actigraphy acquisition, and newborns with severe health conditions.
The invention discloses an antibody targeting CLDN18.2 and a preparation method and application thereof. The antibody comprises a VL and/or a VH comprising the following CDR sequences: a VH CDR1 amino acid sequence shown as SEQ ID NO. 6; VH CDR2 amino acid sequence shown as SEQ ID NO. 7; and/or the VH CDR3 amino acid sequence shown as SEQ ID NO. 8; the VL comprises the CDR sequences: a VL CDR1 amino acid sequence as set forth in SEQ ID NO. 17; a VL CDR2 amino acid sequence as set forth in SEQ ID NO. 18; and/or the VL CDR3 amino acid sequence shown as SEQ ID NO. 19. Compared with the prior art, the antibody has obvious advantages of binding affinity, ADCC, CDC, growth inhibition effect, endocytosis activity and the like.
A method of treating a lesion in a non-human mammal comprises applying thereto a material which is a cellular foetal adjunct of the birth or parturition of said mammal or is derived from such an adjunct, the foetal adjunct having been treated by deep freezing or lyophilisation to resist deterioration on storage, having been stored and having been reactivated after storage and prior to application. Typical cellular foetal adjuncts specified include the amnion, amniotic fluid surrounding the foetus, the yolk-sac associated with the foetus, and the allantois, umbilical, chorionic and placental tissues, and placental blood. The cellular foetal adjunct is preferably applied as a tissue graft directly to the lesion.  In a modification, a tissue derived from a non-human mammal other than the mammal to be treated is applied as a graft over the graft of foetal adjunct tissue.  The therapeutic material derived from the cellular foetal adjunct may be derived by implanting the foetal adjunct in a non-human mammal other than the mammal to be treated and either of the same or a different species, and recovering secondary cells, e.g. lymphatic fluids, or blood, therefrom.
A cosmetic product that includes a cosmetic composition. The cosmetic composition can include an aqueous phase and an initial oil phase. The cosmetic composition is contained in a container. The product also includes indicia for a user to shake the container where shaking the composition breaks the initial oil phase into oil discontinuous phases dispersed in the aqueous phase. The oil discontinuous phase can have a particle size of from about 0.1 mm to about 20 mm and the discontinuous phase can be dispersed for at least 24 hours. The cosmetic product can provide prolonged dispersion of the dispersed oil phases.
PURPOSE:To obtain a new peptide, having an amino acid sequence of Tyr-Val- Pro-Phe-Pro-Pro-Phe and further hypotensive, opioid antagonistic and arterial relaxing activities, etc., and useful as a hypotensive agent, etc. CONSTITUTION:A human milk whole casein is fractionated by gel filtration and a fraction eluted in a void volume is collected to provide a solution containing kappa-casein, etc., and lactoferrin. The resultant fraction is then regulated to pH2 with HCl. Pepsin is subsequently added and reacted at 37 deg.C for 5hr. The pH is then regulated to 7.5 with 1 N NaOH and carboxypeptidase A is subsequently added to carry out reaction at 37 deg.C for 5hr. The obtained hydrolyzate is boiled for 10min and centrifuged to remove insoluble substances. The obtained supernatant is developed with an acetonitrile gradient containing 0.1% trifluoroacetic acid according to high-performance liquid chromatography using a column treated with octadecylsilane to afford the objective new peptide (salt) expressed by the formula Tyr-Val-Pro-Phe-Pro-Pro-Phe.
This includes induction with 4 cycles of ipilimumab and nivolumab X 4 cycles followed by continuation with nivolumab alone every month for 1 year as in standard of care arm. Each induction cycle is 21 days and includes ipilimumab on day 1 plus nivolumab on day 1. In addition, patients will receive 4 weekly doses of Rituxan (first dose intravenously and then 3 weekly doses subcutaneously). First dose of Rituxan will be administered one week following the start of cycle 1 of ipilimumab and nivolumab. All treatments will have a +/-3 business day window for administration.
Administration of CI-581a at 0.8mg/kg during week 1. Administration of CI-581b at 0.025mg/kg during week 3.
This analysis will be based on data from the national electronic based Danish OHCA registry. Data on OHCAs with resuscitative attempts in Denmark have been collected in the electronic based Danish Medical Service report system since 2016. The registry covers detailed data including the EMS report, executive entries, and advanced text searches of prehospital charts. All cases go through an elaborate validation process where all identified events are read through manually by an external verification team. This ensures high quality of data, collected according to the Utstein recommendations, throughout the approximately 5400 cases of OHCA in Denmark annually. During this verification process, supplementary sources of data are linked to each OHCA, among others information about survival, localization, initiation of bystander CPR and EMS personnel operation.
Five veterans with chronic motor complete SCI (AIS A or B) will be recruited to participate in the current trial. The primary objective is to determine how implantation of an epidural stimulator can help to control movement in the leg muscles to stand and perform stepping. Participants will be trained using a robotic suit and parallel bars. The procedure of using epidural stimulation with the robotic suit is experimental. The participant will be scheduled to perform temporary implantation followed by permanent implantation. Seven days later, two 8-electrode arrays of Vectris lead will be implanted in an operating room. The research team will be responsible for helping the participants to trigger the paralyzed muscles from supine and sitting using for 5 days per week. Participants would be required to come for study visits twice daily for 2 hours per day. Each visit will last approximately 1 hour in the morning and 1 hour in the evening. During these visits, participants will practice walking with a robotic suit for 30-60 minutes followed by overground walking between parallel bars, or with a walker or crutches.
FIELD: veterinary medicine. SUBSTANCE: the strain is characterized by a complex of morphological and cultural-biochemical features. It represents straight and slightly curved rods with rounded edges 1X3-6 mcm being single, in pairs and in chains. Upon a broth, long and coiled filaments are formed consisted of several indivisible cells. It is characterized by polymorphism. Oval spores are developed which take up 1/2 - 2/3 cell size. They are located centrally or subterminally with no distinct sporangium bulging. Aerobes are mobile at 38 C optimal growth temperature. Rods are dyed positively according to Gram. Upon a meat-peptone agar, they are growing as grayish-white dull nontransparent flat folded dry colonies of rounded shape and average size (D=5- 10 mm). Colonies are tightly united with a substrate, at 2nd-3d having a yellow- colored shade. It releases catalase, acetoin and acethylmethylcarbon. It releases no indole and hydrogen sulfide. It reduces nitrates and nitrites, hydrolizes a starch. It hydrolizes no hippurate. It disintegrates glucose, saccharose, lactose and mannitol by developing an acid, not a gas. It releases proteolytic ferments, gelatin is diluted by a funnel, then - by layers. EFFECT: decreased average duration of therapy against the known "Sporobacterine" preparation. 2 ex _
BACKGROUND: Increasing proportions of geriatric patients pose tremendous challenges for our society. Developments in assistive technologies have the potential to support older and frail people in aging and care. To reach a sustainable adoption of these technologies, the perceptions and wishes of future users must be understood. In particular, the relationships between individual health-related factors, and the perceptions of aging and using assistive technologies in severe health situations must be empirically examined.
METHODS: Addressing this research gap, our quantitative study (N = 570) investigates the impact of diverse future users' age and health status on their a) perceptions of aging, b) perceptions and acceptance of using assistive technologies in aging and care, as well as c) end-of-life decisions regarding technology usage. For this, four groups were segmented for the comparison of younger (< 50 years) healthy, younger chronically ill, older (50 + years) healthy, and older chronically ill participants.
RESULTS: The results revealed that health status is more decisive for age-related perceptions compared to age. The technology-related perceptions were slightly impacted by either chronological age or health status. The end-of-life decisions showed the most striking differences in the willingness to use assistive technologies, revealing older chronically ill participants to have more restrained attitudes towards technology usage than older healthy as well as all younger participants.
CONCLUSIONS: The findings suggest that the benefits of assistive technologies in private or professional care contexts should be communicated and implemented tailored to the respective user group's needs. Moreover, the results allow us to derive practical implications within the geriatric care context.
Fluid loss from circulating plasma volume is one of the contributors of oedema formation. Measurement of colloid osmotic pressure (COP) both in plasma and in interstitial fluid can be utilised in planing of fluid therapy in patients with oedema. Different methods of sampling interstitial fluid are well validated in animal models, but not in human. Sampling of interstitial fluid by subcutaneous sewn wicks is a well-known method and can be painful. Local anaesthetics can reduce pain. By comparing interstitial fluid taken from areas with or without application of local anaesthetics, a possible influence in COP values can be detected.
Disentangling the impact of the weather on transmission of infectious diseases is crucial for health protection, preparedness and prevention. Because weather factors are co-incidental and partly correlated, we have used geography to separate out the impact of individual weather parameters on other seasonal variables using campylobacteriosis as a case study. Campylobacter infections are found worldwide and are the most common bacterial food-borne disease in developed countries, where they exhibit consistent but country specific seasonality. We developed a novel conditional incidence method, based on classical stratification, exploiting the long term, high-resolution, linkage of approximately one-million campylobacteriosis cases over 20 years in England and Wales with local meteorological datasets from diagnostic laboratory locations. The predicted incidence of campylobacteriosis increased by 1 case per million people for every 5° (Celsius) increase in temperature within the range of 8°-15°. Limited association was observed outside that range. There were strong associations with day-length. Cases tended to increase with relative humidity in the region of 75-80%, while the associations with rainfall and wind-speed were weaker. The approach is able to examine multiple factors and model how complex trends arise, e.g. the consistent steep increase in campylobacteriosis in England and Wales in May-June and its spatial variability. This transparent and straightforward approach leads to accurate predictions without relying on regression models and/or postulating specific parameterisations. A key output of the analysis is a thoroughly phenomenological description of the incidence of the disease conditional on specific local weather factors. The study can be crucially important to infer the elusive mechanism of transmission of campylobacteriosis; for instance, by simulating the conditional incidence for a postulated mechanism and compare it with the phenomenological patterns as benchmark. The findings challenge the assumption, commonly made in statistical models, that the transformed mean rate of infection for diseases like campylobacteriosis is a mere additive and combination of the environmental variables.
BACKGROUND: The initiation of migraine headaches and the involvement of neuroinflammatory signaling between parenchymal and meningeal cells remain unclear. Experimental evidence suggests that a cascade of inflammatory signaling originating from neurons may extend to the meninges, thereby inducing neurogenic inflammation and headache. This review explores the role of parenchymal inflammatory signaling in migraine headaches, drawing upon recent advancements. BODY: Studies in rodents have demonstrated that sterile meningeal inflammation can stimulate and sensitize meningeal nociceptors, culminating in headaches. The efficacy of relatively blood-brain barrier-impermeable anti-calcitonin gene-related peptide antibodies and triptans in treating migraine attacks, both with and without aura, supports the concept of migraine pain originating in meninges. Additionally, PET studies utilizing inflammation markers have revealed meningeal inflammatory activity in patients experiencing migraine with aura, particularly over the occipital cortex generating visual auras. The parenchymal neuroinflammatory signaling involving neurons, astrocytes, and microglia, which eventually extends to the meninges, can link non-homeostatic perturbations in the insensate brain to pain-sensitive meninges. Recent experimental research has brought deeper insight into parenchymal signaling mechanisms: Neuronal pannexin-1 channels act as stress sensors, initiating the inflammatory signaling by inflammasome formation and high-mobility group box-1 release in response to transient perturbations such as cortical spreading depolarization (CSD) or synaptic metabolic insufficiency caused by transcriptional changes induced by migraine triggers like sleep deprivation and stress. After a single CSD, astrocytes respond by upregulating the transcription of proinflammatory enzymes and mediators, while microglia are involved in restoring neuronal structural integrity; however, repeated CSDs may prompt microglia to adopt a pro-inflammatory state. Transcriptional changes from pro- to anti-inflammatory within 24 h may serve to dampen the inflammatory signaling. The extensive coverage of brain surface and perivascular areas by astrocyte endfeet suggests their role as an interface for transporting inflammatory mediators to the cerebrospinal fluid to contribute to meningeal nociception.
CONCLUSION: We propose that neuronal stress induced by CSD or synaptic activity-energy mismatch may initiate a parenchymal inflammatory signaling cascade, transmitted to the meninges, thereby triggering lasting headaches characteristic of migraine, with or without aura. This neuroinflammatory interplay between parenchymal and meningeal cells points to the potential for novel targets for migraine treatment and prophylaxis.
PCT No. PCT/SE95/00348 Sec. 371 Date Sep. 17, 1996 Sec. 102(e) Date Sep. 17, 1996 PCT Filed Mar. 31, 1995 PCT Pub. No. WO95/26750 PCT Pub. Date Oct. 12, 1995The present invention relates to a pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration comprising coagulation factor VIII or factor IX and use thereof for manufacture of a medicament for treating haemophilia A or B. The formulation comprises coagulation factor VIII or factor IX with an activity of at least 200 IU/ml and an additive increasing the bio-availability of factor VIII or factor IX. Tests with factor VIII gives a therapeutic level of active factor VIII in the blood stream for a surprisingly long period of time after subcutaneous, intramuscular or intradermal administration. The factor VIII is suitably a highly purified recombinant factor VII, and preferably a deletion derivative thereof, which can be used for the manufacture of a medicament for subcutaneous administration.
The present invention relates to a medicament with an analgesic, antipyretic and/or antiinflammatory effect based on a salicylic acid derivative. The state of the art is always searching for alternatives to active ingredients such as acetylsalicylic acid (ASA) and ethenzamide in order to eliminate intolerance or to be able to offer simpler and better ingredients, which act as rapidly as possible, for a wide variety of possible administrations. Surprisingly, the invention has now succeeded in demonstrating that ethenzamide is very rapidly and completely metabolised in the human body to 2-Ethoxybenzoic acid. Ethenzamide is only a prodrug. It was possible to rule out metabolism to salicylamide. It was likewise possible to demonstrate the analgesic effect of 2-ethoxybenzoic acid. It correlates with the serum levels and persists for more than 8 hours. 2-Ethoxybenzoic acid is very rapidly absorbed. The serum maxima are reached after only 30 minutes; 2-ethoxybenzoic acid is still detectable in the serum even after 24 hours. These properties make 2-ethoxybenzoic acid an ideal analgesic which has a rapid onset of action and which has no effect on blood coagulation. Since the bioavailability is higher, it is also possible to reduce the single doses. By virtue of the physicochemical properties of 2-ethoxybenzoic acid, use in the form of a solution is possible so that, besides solid drug forms for oral and rectal use, it is also possible to prepare and use liquid formulations such as solutions for administration as drops or by injection. <IMAGE>
Aim: The goal of this market research study was to determine the usability of a single-dose prefilled injector (SelfJect™) for administration of Acthar® Gel (manufactured by Mallinckrodt Pharmaceuticals, UK) in patients with inflammatory diseases by obtaining feedback from patient and practitioner user groups in the US. Materials & methods: Patients and healthcare professionals (HCPs) representing relevant therapeutic areas were enrolled in the study between February and March 2021. SelfJect was mailed to patients and HCPs prior to 90-min virtual video-recorded focus group sessions and 60-min 1:1 virtual interviews, respectively. Patients completed an online assignment prior to the group session, which included instructions on how to use SelfJect and questions about their initial reaction while handling the device. HCPs were instructed to not open the package until the interview. Feedback from patients and HCPs were captured by open-ended questions and ranking scales. Results: Twelve patients and 42 HCPs participated in the study. Most patients (9/12 [75%]) and HCPs (38/42 [90%]) had experience with injectable medications, and 7/12 (58%) and 30/42 [71%] had experience with Acthar injections, respectively. Most patients and HCPs reported that key benefits of SelfJect were accurate dose delivery and ease of use, including the ergonomic handle and elimination of drawing Acthar from a vial into a syringe. Patients expressed some concerns about storage and disposal, but the need to store SelfJect would not deter them from using it. Most patients (9/12 [75%]) felt prepared to inject Acthar after reviewing the instructions. HCPs anticipated that 75% to 100% of patients would benefit switching from the vial to SelfJect. Conclusion: All participants expressed positive perceptions for SelfJect including easy use, few preparation steps and potential reduced anxiety due to needle phobia. These attributes may help treatment adherence for patients and caregivers.
Skin aging is a process of deterioration in the physiological structure and function of the skin that significantly increases in the 4th and 5th decades of life. Skin aging is a combination of physiological and pathological aging. Physiological change cannot be avoided and mandatory for everyone, pathological aging ir extrinsic aging is an abnormal skin condition caused by cigarettes, pollution and ultraviolet (UV). In general, the clinical characteristics of skin aging consist of pigmentation changes, hydration disorders, the appearance of wrinkles and skin tumors. The photoaging assessment was first proposed in 1996 by Dr. Richard Glogau, The Glogau scale assesses photoaging based on clinical assessment grouped into 4 categories, namely types I, II, III, and IV,where each type is graded by the severity of wrinkles, namely from mild, moderate, advanced, and severe. Isik et al. developed an instrument for quantitative skin aging assessment using dermoscopy. This examination is non-invasive and is expected to provide a more objective assessment. There are four facial regions assessed in the DPAS score calculation: forehead, right cheek, left cheek, and chin. The sum of the scores of the four regions is assessed based on 11 parameters, with a maximum final score of 44. Telomeres are repetitive DNA-Protein complexes located at the ends of chromosomes of eukarotic cells, and their function is to maintain chromosome stability during cell division, by protecting chromosomes from degradation and fusion. Many factors affect telomere length, such as body mass index, hormonal therapy, antioxidant intake, chronic diseases, and gender. Research by son et al. found that telomere length shortening was validated to increase the odds of skin aging (OR=0.96, 95% CI: 0.9332-0.99566, P= 0.03) Telomeres are closely linked to cellular aging, especially in dermal cells and telomere shortening in skin fibroblasts may lead to epidermal aging and barrier function defectcs.